Clinicopathologic significance of MYD88 L265P mutation in diffuse large B-cell lymphoma: a meta-analysis

The precise clinicopathologic significance of myeloid differentiation primary response gene ( MYD88) L265P mutation in diffuse large B-cell lymphomas (DLBCLs) remains elusive. To investigate the frequency and clinicopathologic significance of the MYD88 L265P mutation in DLBCLs, we conducted a meta-a...

Full description

Saved in:
Bibliographic Details
Published in:Scientific reports 2017-05, Vol.7 (1), p.1785-8, Article 1785
Main Authors: Lee, Ju-Han, Jeong, Hoiseon, Choi, Jung-Woo, Oh, HwaEun, Kim, Young-Sik
Format: Article
Language:English
Subjects:
692/4028/67/1990/291/1621/1915
692/53/2421
Age Factors
Amino Acid Substitution
B-cell lymphoma
Biomarkers, Tumor
Central nervous system
Codon
Female
Humanities and Social Sciences
Humans
Lymphocytes B
Lymphoma
Lymphoma, Large B-Cell, Diffuse - diagnosis
Lymphoma, Large B-Cell, Diffuse - genetics
Lymphoma, Large B-Cell, Diffuse - mortality
Male
Meta-analysis
multidisciplinary
Mutation
Mutation Rate
Mutation rates
MyD88 protein
Myeloid Differentiation Factor 88 - genetics
Neoplasm Staging
Odds Ratio
Prognosis
Proportional Hazards Models
Publication Bias
Science
Science (multidisciplinary)
Testes
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The precise clinicopathologic significance of myeloid differentiation primary response gene ( MYD88) L265P mutation in diffuse large B-cell lymphomas (DLBCLs) remains elusive. To investigate the frequency and clinicopathologic significance of the MYD88 L265P mutation in DLBCLs, we conducted a meta-analysis of 40 published studies on 2736 DLBCL patients. We collected relevant published research findings identified using the PubMed and Embase databases. The effect sizes of outcome parameters were calculated using a random-effects model. In this meta-analysis, the MYD88 L265P mutation in DLBCL showed a significant difference according to tumor sites. The overall incidence of the MYD88 L265P mutation in DLBCLs, excluding the central nervous system and testicular DLBCLs, was 16.5%. Notably, the MYD88 L265P mutation rates of CNS and testicular DLBCL patients were 60% and 77%, respectively. Interestingly, the MYD88 L265P mutation was more frequently detected in activated B-cell-like (ABC) or non-germinal center B-cell-like (GCB) than GCB subtype (OR = 3.414, p 
ISSN:2045-2322
2045-2322
DOI:10.1038/s41598-017-01998-5